5 research outputs found

    You, Too, Will Speak English Soon: The Pros and Cons of English as a Business Lingua Franca

    Get PDF
    This paper discusses the increasing use of English as a Business Lingua Franca (BELF). In particular, this paper examines case studies from several companies located in diverse countries (Japan, Germany, and Finland), where English has been implemented as an internal lingua franca. The case studies show that most employees at these companies adjusted to BELF in a very pragmatic manner, while others considered the employment of BELF to be an intrusive course of action. This paper also investigates how BELF is viewed by native speakers of English and argues that attitudes towards foreign language learning by native speakers of English may constitute an impediment to efficient communication between speakers of different native languages and backgrounds. Finally, this papers shows that the acceptance of BELF, at least to a certain degree, is dependent on attitudes towards the global spread of English

    Digital Divide: Low German and other Minority Languages

    No full text
    This paper investigates the online presence of Low German, a minority language spoken in northern Germany, as well as several other European regional and minority languages. In particular, this article presents the results of two experiments, one involving Wikipedia and one involving Twitter, that assess whether and to which extent minority languages are used on these websites. The article argues that minority and regional languages are not only underrepresented online due to a combination of historical, linguistic, sociological, and demographic reasons, but that the overall architecture of the World Wide Web and its most visited websites is such that smaller languages do not stand a chance to gain a meaningful online presence.

    Global variations in heart failure etiology, management, and outcomes

    No full text
    Importance: Most epidemiological studies of heart failure (HF) have been conducted in high-income countries with limited comparable data from middle- or low-income countries. Objective: To examine differences in HF etiology, treatment, and outcomes between groups of countries at different levels of economic development. Design, Setting, and Participants: Multinational HF registry of 23 341 participants in 40 high-income, upper–middle-income, lower–middle-income, and low-income countries, followed up for a median period of 2.0 years. Main Outcomes and Measures: HF cause, HF medication use, hospitalization, and death. Results: Mean (SD) age of participants was 63.1 (14.9) years, and 9119 (39.1%) were female. The most common cause of HF was ischemic heart disease (38.1%) followed by hypertension (20.2%). The proportion of participants with HF with reduced ejection fraction taking the combination of a β-blocker, renin-angiotensin system inhibitor, and mineralocorticoid receptor antagonist was highest in upper–middle-income (61.9%) and high-income countries (51.1%), and it was lowest in low-income (45.7%) and lower–middle-income countries (39.5%) (P < .001). The age- and sex- standardized mortality rate per 100 person-years was lowest in high-income countries (7.8 [95% CI, 7.5-8.2]), 9.3 (95% CI, 8.8-9.9) in upper–middle-income countries, 15.7 (95% CI, 15.0-16.4) in lower–middle-income countries, and it was highest in low-income countries (19.1 [95% CI, 17.6-20.7]). Hospitalization rates were more frequent than death rates in high-income countries (ratio = 3.8) and in upper–middle-income countries (ratio = 2.4), similar in lower–middle-income countries (ratio = 1.1), and less frequent in low-income countries (ratio = 0.6). The 30-day case-fatality rate after first hospital admission was lowest in high-income countries (6.7%), followed by upper–middle-income countries (9.7%), then lower–middle-income countries (21.1%), and highest in low-income countries (31.6%). The proportional risk of death within 30 days of a first hospital admission was 3- to 5-fold higher in lower–middle-income countries and low-income countries compared with high-income countries after adjusting for patient characteristics and use of long-term HF therapies. Conclusions and Relevance: This study of HF patients from 40 different countries and derived from 4 different economic levels demonstrated differences in HF etiologies, management, and outcomes. These data may be useful in planning approaches to improve HF prevention and treatment globally
    corecore